Isofol completes recruitment of Japanese patients in the global phase III AGENT study
GOTHENBURG, Sweden, May 6, 2021 – In December 2020, Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: […]
Corporate Information
Isofol receives notice that Clinical Use Patent in Europe for Drug Candidate arfolitixorin will be approved
GOTHENBURG, Sweden, March 22, 2021 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), today announced that
Invitation to a conference call and webcast in connection with Isofol receiving recommendation to complete the global Phase III AGENT study for market registration as planned with 440 patients
GOTHENBURG, Sweden, March 22, 2021 – Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) announced on
Isofol receives recommendation from iDSMB to complete the global Phase III AGENT study for market registration as planned with 440 patients
GOTHENBURG, Sweden, March 19, 2021 – Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) announces that
Isofol to present gene expression results from the completed Phase I/IIa ISO-CC-005 study today at ASCO-GI 2021 and updates of the timing of the interim analysis in the AGENT study
GOTHENBURG, Sweden, January 15, 2021 – Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) announces that
Isofol reaches 440 patients in global Phase III AGENT study
GOTHENBURG, Sweden, December 9, 2020 – Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) announces that
Invitation to a conference call and webcast by Isofol in connection with the entered license agreement for Paladin Labs Inc. to commercialize arfolitixorin in Canada
GOTHENBURG, Sweden, November 2, 2020 – Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) has today
Isofol announces licensing agreement for Paladin Labs Inc. to commercialize arfolitixorin in Canada
GOTHENBURG, Sweden, November 2, 2020 – Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) is pleased
55 % Overall Response Rate on the safety extension cohorts of the ISO-CC-005 Phase I/IIa study
GOTHENBURG, Sweden, September 30, 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), today provided an
Strengthened patent protection for arfolitixorin in Japan
GOTHENBURG, Sweden, September 1, 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), has announced today